Skip to main content
Erschienen in: Rheumatology International 12/2018

22.08.2018 | Systematic Review

Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review

verfasst von: Olivia Qiu, Theresa Chan, Matthew Luen, Joseph E. Cruz, Evelyn R. Hermes-DeSantis

Erschienen in: Rheumatology International | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Raynaud’s phenomenon (RP) is a microvascular condition in which reversible ischemic attacks occur in the extremities. Due to the unpredictable nature of these attacks, pharmacologic agents that can be administered on as-needed basis are currently being sought after. Topical nitrates are well suited for as-needed use, and several different formulations have been studied for the treatment of RP, including ointments, gels, patches, and tapes. However, these different dosage forms are not all equal in terms of safety and efficacy, and not every one is commercially available for use in clinical practice. Nitroglycerin ointment is commercially available, and it has less systemic side effects than other topical formulations. Since its role in the treatment of RP has not yet been completely established, we performed a systematic search of Medline, Embase, and the Cochrane Central Register of Controlled Trials to evaluate its safety and efficacy. A total of 1125 studies were identified, and 7 were included in our review. Although the included studies used different measures of efficacy, the majority reported positive responses to nitroglycerin ointment. The benefit of nitroglycerin ointment in the treatment of RP may be further realized through more robust investigation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Belch J, Carlizza A, Carpentier PH et al (2017) ESVM guidelines—the diagnosis and management of Raynaud’s phenomenon. VASA 46:413–423CrossRef Belch J, Carlizza A, Carpentier PH et al (2017) ESVM guidelines—the diagnosis and management of Raynaud’s phenomenon. VASA 46:413–423CrossRef
2.
Zurück zum Zitat Maverakis E, Patel F, Kronenberg DG et al (2014) International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun 48:60–65CrossRef Maverakis E, Patel F, Kronenberg DG et al (2014) International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun 48:60–65CrossRef
3.
Zurück zum Zitat Hughes M, Snapir A, Wilkinson J et al (2015) Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception. Rheumatology 54:1443–1447CrossRef Hughes M, Snapir A, Wilkinson J et al (2015) Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception. Rheumatology 54:1443–1447CrossRef
4.
Zurück zum Zitat Thompson AE, Shea B, Welch V et al (2001) Calcium channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847CrossRef Thompson AE, Shea B, Welch V et al (2001) Calcium channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847CrossRef
5.
Zurück zum Zitat Ennis H, Hughes M, Anderson ME et al (2016) Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev 2:CD002069PubMed Ennis H, Hughes M, Anderson ME et al (2016) Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev 2:CD002069PubMed
6.
Zurück zum Zitat Rirash F, Tingey PC, Harding SE et al (2017) Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev 12:CD000467PubMed Rirash F, Tingey PC, Harding SE et al (2017) Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev 12:CD000467PubMed
7.
Zurück zum Zitat Herrick AL (2008) Raynaud’s phenomenon (secondary). BMJ Clin Evid (Online) 09:1125 Herrick AL (2008) Raynaud’s phenomenon (secondary). BMJ Clin Evid (Online) 09:1125
8.
Zurück zum Zitat McMahan ZH, Wigley FM (2010) Raynaud’s phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management. Int J Clin Rheumtol 5(3):355–370CrossRef McMahan ZH, Wigley FM (2010) Raynaud’s phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management. Int J Clin Rheumtol 5(3):355–370CrossRef
9.
Zurück zum Zitat Herrick AL (2016) Recent advances in the pathogenesis and management of Raynaud’s phenomenon and digital ulcers. Curr Opin Rheumatol 28:577–585CrossRef Herrick AL (2016) Recent advances in the pathogenesis and management of Raynaud’s phenomenon and digital ulcers. Curr Opin Rheumatol 28:577–585CrossRef
10.
Zurück zum Zitat Roustit M, Blaise S, Allanore Y et al (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696–1699CrossRef Roustit M, Blaise S, Allanore Y et al (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696–1699CrossRef
11.
Zurück zum Zitat Schiopu E, Hsu VM, Impens AJ et al (2009) Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol 36:2264–2268CrossRef Schiopu E, Hsu VM, Impens AJ et al (2009) Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol 36:2264–2268CrossRef
12.
Zurück zum Zitat Caglayan E, Axmann S, Hellmich M et al (2012) Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 172:1182–1184CrossRef Caglayan E, Axmann S, Hellmich M et al (2012) Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 172:1182–1184CrossRef
13.
Zurück zum Zitat Fries R, Shariat K, von Wilmowsky H et al (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985CrossRef Fries R, Shariat K, von Wilmowsky H et al (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985CrossRef
14.
Zurück zum Zitat Shenoy PD, Kumar S, Jha LK et al (2010) Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology 49:2420–2428CrossRef Shenoy PD, Kumar S, Jha LK et al (2010) Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology 49:2420–2428CrossRef
15.
Zurück zum Zitat Herrick AL, van den Hoogen F, Gabrielli A et al (2011) Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63:775–782CrossRef Herrick AL, van den Hoogen F, Gabrielli A et al (2011) Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63:775–782CrossRef
16.
Zurück zum Zitat Agarwal V, Ghosh P, Sharma A et al (2010) Efficacy of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo-controlled parallel group multicentric study (abstract). Arthritis Rheum 62(suppl 10):2086 Agarwal V, Ghosh P, Sharma A et al (2010) Efficacy of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo-controlled parallel group multicentric study (abstract). Arthritis Rheum 62(suppl 10):2086
17.
Zurück zum Zitat Nossaman VE, Nossaman BD, Kadowitz PJ (2010) Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev 18:190–197CrossRef Nossaman VE, Nossaman BD, Kadowitz PJ (2010) Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev 18:190–197CrossRef
18.
Zurück zum Zitat Wigley FM, Flavahan NA (2016) Raynaud’s phenomenon. N Engl J Med 375:556–565CrossRef Wigley FM, Flavahan NA (2016) Raynaud’s phenomenon. N Engl J Med 375:556–565CrossRef
19.
Zurück zum Zitat Kleckner MS, Allen EV, Wakim KG (1951) The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud’s disease and Raynaud’s phenomenon: studies on blood flow and clinical manifestations. Circulation 3:681–689CrossRef Kleckner MS, Allen EV, Wakim KG (1951) The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud’s disease and Raynaud’s phenomenon: studies on blood flow and clinical manifestations. Circulation 3:681–689CrossRef
20.
Zurück zum Zitat Fischer M, Reinhold B, Falck H et al (1985) Topical nitroglycerin ointment in Raynaud’s phenomenon. Z Kardiol 74:298–302PubMed Fischer M, Reinhold B, Falck H et al (1985) Topical nitroglycerin ointment in Raynaud’s phenomenon. Z Kardiol 74:298–302PubMed
21.
Zurück zum Zitat Anderson ME, Moore TL, Hollis S et al (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology 41:324–328CrossRef Anderson ME, Moore TL, Hollis S et al (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology 41:324–328CrossRef
22.
Zurück zum Zitat Hughes M, Moore T, Manning J et al (2017) Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate. Microvas Res 111:32–36CrossRef Hughes M, Moore T, Manning J et al (2017) Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate. Microvas Res 111:32–36CrossRef
23.
Zurück zum Zitat Coppock JS, Hardman JM, Bacon PA et al (1986) Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud’s phenomenon. Postgrad Med J 62:15–18CrossRef Coppock JS, Hardman JM, Bacon PA et al (1986) Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud’s phenomenon. Postgrad Med J 62:15–18CrossRef
24.
Zurück zum Zitat Kleckner MS, Allen EV, Wakim KG (1950) Use of glyceryl trinitrate (nitroglycerin) ointment in the treatment of Raynaud’s disease and Raynaud’s phenomenon. Proc Staff Meet Mayo Clin 25:657–659PubMed Kleckner MS, Allen EV, Wakim KG (1950) Use of glyceryl trinitrate (nitroglycerin) ointment in the treatment of Raynaud’s disease and Raynaud’s phenomenon. Proc Staff Meet Mayo Clin 25:657–659PubMed
25.
Zurück zum Zitat Franks AG (1982) Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1:76–77CrossRef Franks AG (1982) Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1:76–77CrossRef
26.
Zurück zum Zitat Teh LS, Manning J, Moore T et al (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 34:636–641CrossRef Teh LS, Manning J, Moore T et al (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 34:636–641CrossRef
27.
Zurück zum Zitat Nahir AM, Schapira D, Scharf Y (1986) Double-blind randomized trial of Nitroderm TTS in the treatment of Raynaud’s phenomenon. Isr J Med Sci 22:139–142PubMed Nahir AM, Schapira D, Scharf Y (1986) Double-blind randomized trial of Nitroderm TTS in the treatment of Raynaud’s phenomenon. Isr J Med Sci 22:139–142PubMed
28.
Zurück zum Zitat Chung L, Shapiro L, Fiorentino D et al (2009) MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized controlled trial. Arthritis Rheum 60:870–877CrossRef Chung L, Shapiro L, Fiorentino D et al (2009) MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized controlled trial. Arthritis Rheum 60:870–877CrossRef
29.
Zurück zum Zitat Hummers LK, Dugowson CE, Dechow FJ et al (2013) A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerin, in patients with Raynaud phenomenon. Ann Rheum Dis 72:1962–1967CrossRef Hummers LK, Dugowson CE, Dechow FJ et al (2013) A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerin, in patients with Raynaud phenomenon. Ann Rheum Dis 72:1962–1967CrossRef
30.
Zurück zum Zitat Tucker AT, Pearson RM, Cooke ED et al (1999) Effect of nitric-oxide generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet 354:1670–1675CrossRef Tucker AT, Pearson RM, Cooke ED et al (1999) Effect of nitric-oxide generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet 354:1670–1675CrossRef
31.
Zurück zum Zitat Curtiss P, Schwager Z, Cobos G et al (2018) A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol 78:1110–1118CrossRef Curtiss P, Schwager Z, Cobos G et al (2018) A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol 78:1110–1118CrossRef
32.
Zurück zum Zitat Todd B (1986) Transdermal nitroglycerin ointment and patches. Geriatr Nurs 7:152–154CrossRef Todd B (1986) Transdermal nitroglycerin ointment and patches. Geriatr Nurs 7:152–154CrossRef
33.
Zurück zum Zitat Nitroglycerin [monograph]. In: Lexicomp Online [online database]. Hudson, OH: Lexi-Comp. Accessed 22 Apr 18 Nitroglycerin [monograph]. In: Lexicomp Online [online database]. Hudson, OH: Lexi-Comp. Accessed 22 Apr 18
34.
Zurück zum Zitat Moinzadeh P, Riemekasten G, Siegert E et al (2016) Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. J Rheumatol 43:66–74CrossRef Moinzadeh P, Riemekasten G, Siegert E et al (2016) Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. J Rheumatol 43:66–74CrossRef
35.
Zurück zum Zitat Foguera (2009) Nitro-bid (nitroglycerin ointment) [package insert]. Foguera, Melville Foguera (2009) Nitro-bid (nitroglycerin ointment) [package insert]. Foguera, Melville
36.
Zurück zum Zitat Bose N, Bena J, Chatterjee S (2015) Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther 17:44CrossRef Bose N, Bena J, Chatterjee S (2015) Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther 17:44CrossRef
37.
Zurück zum Zitat Rosato E, Molinaro I, Borghese F et al (2010) Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 37:2531–2539CrossRef Rosato E, Molinaro I, Borghese F et al (2010) Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 37:2531–2539CrossRef
38.
Zurück zum Zitat Merkel PA, Herlyn K, Martin RW et al (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 46:2410–2420CrossRef Merkel PA, Herlyn K, Martin RW et al (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 46:2410–2420CrossRef
Metadaten
Titel
Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review
verfasst von
Olivia Qiu
Theresa Chan
Matthew Luen
Joseph E. Cruz
Evelyn R. Hermes-DeSantis
Publikationsdatum
22.08.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 12/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4119-9

Weitere Artikel der Ausgabe 12/2018

Rheumatology International 12/2018 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to referees

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.